Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology01:23

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Associations between structural brain changes and blood neurofilament light chain protein in treatment-resistant schizophrenia.

The Australian and New Zealand journal of psychiatry·2025
Same author

Plasma neurofilament light outperforms glial fibrillary acidic protein in differentiating behavioural variant frontotemporal dementia from primary psychiatric disorders.

Journal of the neurological sciences·2024
Same author

Plasma neurofilament light protein is differentially associated with age in individuals with treatment-resistant schizophrenia and bipolar affective disorder compared to controls.

Psychiatry research·2024
Same author

Associations between structural brain changes and blood neurofilament light chain protein in treatment-resistant schizophrenia.

medRxiv : the preprint server for health sciences·2024
Same author

Prediction of treatment response to antipsychotic drugs for precision medicine approach to schizophrenia: randomized trials and multiomics analysis.

Military Medical Research·2023
Same author

Delineating gene-environment effects using virtual twins of patients treated with clozapine.

CPT: pharmacometrics & systems pharmacology·2022

Video Experimental Relacionado

Updated: Jul 10, 2026

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Indicadores proteómicos en el trastorno neurocognitivo del VIH.

Ian Everall1, Igor Grant

  • 1Section of Experimental Neuropathology and Psychiatry, Institute of Psychiatry, King's College, London SE5 8AF, UK. i.everall@iop.kcl.ac.uk

Lancet (London, England)
|April 6, 2004
PubMed
Resumen

No abstract available in PubMed .

Más Videos Relacionados

A Rat Model of EcoHIV Brain Infection
08:48

A Rat Model of EcoHIV Brain Infection

Published on: January 21, 2021

Identification of EcoHIV-Infected Cells in Microglia-Manipulated Transgenic Mice
07:23

Identification of EcoHIV-Infected Cells in Microglia-Manipulated Transgenic Mice

Published on: December 20, 2024

Videos de Experimentos Relacionados

Last Updated: Jul 10, 2026

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

A Rat Model of EcoHIV Brain Infection
08:48

A Rat Model of EcoHIV Brain Infection

Published on: January 21, 2021

Identification of EcoHIV-Infected Cells in Microglia-Manipulated Transgenic Mice
07:23

Identification of EcoHIV-Infected Cells in Microglia-Manipulated Transgenic Mice

Published on: December 20, 2024